0.9068

12.80% -0.1333

Atyr Pharma Inc (ATYR)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$1.04

Offen:

$1.03

24-Stunden-Volumen:

909.18K

Relative Volume:

0.73

Marktkapitalisierung:

$88.92M

Einnahmen:

$190.00K

Nettoeinkommen (Verlust:

$-74.12M

KGV:

-1.1388

EPS:

-0.7962

Netto-Cashflow:

$-62.06M

1W Leistung:

+12.32%

1M Leistung:

+14.05%

6M Leistung:

+11.01%

1J Leistung:

-71.30%

1-Tages-Spanne:

$0.90

$1.03

1-Wochen-Bereich:

$0.811

$1.05

52-Wochen-Spanne:

$0.64

$7.2904

Atyr Pharma Inc Stock (ATYR) Company Profile

Firmenname

Atyr Pharma Inc

Sektor

Healthcare (1115)

Branche

Biotechnology (621)

Telefon

(858) 731-8389

Adresse

10240 SORRENTO VALLEY ROAD, SAN DIEGO

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-05-06

Neueste SEC-Einreichungen

ATYR's Discussions on Twitter

Compare ATYR vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATYR Atyr Pharma Inc	0.9069	101.97M	190.00K	-74.12M	-62.06M	-0.7962
VRTX Vertex Pharmaceuticals Inc	426.18	108.54B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	707.60	75.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	782.06	50.22B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.42	40.45B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	314.22	32.51B	5.36B	287.73M	924.18M	2.5229

Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-16	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-09-15	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2025-09-15	Herabstufung	H.C. Wainwright	Buy → Neutral
2025-09-15	Herabstufung	Leerink Partners	Outperform → Market Perform
2025-09-15	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-02-18	Eingeleitet	Leerink Partners	Outperform
2025-01-06	Eingeleitet	Cantor Fitzgerald	Overweight
2024-10-04	Eingeleitet	Wells Fargo	Overweight
2024-09-05	Eingeleitet	Jefferies	Buy
2023-07-05	Herabstufung	Oppenheimer	Outperform → Perform
2021-10-12	Eingeleitet	RBC Capital Mkts	Outperform
2021-09-21	Eingeleitet	Piper Sandler	Overweight
2021-05-10	Eingeleitet	Laidlaw	Buy
2020-08-17	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-03-04	Eingeleitet	ROTH Capital	Buy
2020-03-02	Eingeleitet	Oppenheimer	Outperform
2018-02-14	Herabstufung	JP Morgan	Neutral → Underweight
2017-09-07	Eingeleitet	Piper Jaffray	Overweight
2016-12-13	Herabstufung	JP Morgan	Overweight → Neutral
2015-12-16	Eingeleitet	Citigroup	Neutral
2015-06-01	Eingeleitet	Citigroup	Buy
2015-06-01	Eingeleitet	JP Morgan	Overweight

Alle ansehen

Atyr Pharma Inc Aktie (ATYR) Neueste Nachrichten

May 06, 2026

MSN Money - MSN

May 06, 2026

Apr 29, 2026

Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com

Apr 29, 2026

aTyr Pharma (ATYR) Projected to Post Earnings on Wednesday - MarketBeat

Apr 29, 2026

Apr 28, 2026

Interstitial Lung Disease Pipeline Grows as 120+ Pharma - openPR.com

Apr 28, 2026

Apr 21, 2026

What is the growth outlook for aTyr Pharma (ATYR) stock (Range-Bound) 2026-04-20Entry Points - Xã Thanh Hà

Apr 21, 2026

Apr 20, 2026

aTyr Pharma Inc stock (US53227K1025): Is efzofitimod's Phase 3 data the real test for pulmonary sarc - AD HOC NEWS

Apr 20, 2026

aTyr Pharma stock tanks after missing main goal in lung disease study - MSN

Apr 20, 2026

aTyr Pharma (ATYR) Stock: This Quarter (Near Highs) 2026-04-20Community Chart Signals - Cổng thông tin điện tử Tỉnh Sơn La

Apr 20, 2026

Apr 19, 2026

aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Apr 19, 2026

Apr 18, 2026

aTyr Pharma (ATYR) Stock Commodity Trade (Investors Pile In) 2026-04-18Shared Momentum Picks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 18, 2026

Apr 16, 2026